<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tenoxicam</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00469</strong>&#160; (APRD00011)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00469/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00469/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00469.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00469.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00469.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00469.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00469.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00469">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Tenoxicam</td><td>German/Spanish</td><td>INN</td></tr><tr><td>T&#233;noxicam</td><td>French</td><td>INN</td></tr><tr><td>Tenoxicamum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Mobiflex</td><td>Roche</td></tr><tr><td>Octiveran</td><td>Rafarm</td></tr><tr><td>Oxicam</td><td>ACI</td></tr><tr><td>Oxytel</td><td>Coup</td></tr><tr><td>Palitenox</td><td>Pharmathen</td></tr><tr><td>Tenorix</td><td>Orion</td></tr><tr><td>Tenxil</td><td>Unison</td></tr><tr><td>Tilcotil</td><td>Meda</td></tr><tr><td>Tilflam</td><td>Dexa Medica</td></tr><tr><td>Tilko</td><td>Ko&#231;ak</td></tr><tr><td>Tilnoxcam</td><td>T. O. Chemicals</td></tr><tr><td>Tiloxican</td><td>Hexal</td></tr><tr><td>Tobitil</td><td>Ranbaxy</td></tr><tr><td>Tonox</td><td>Utopian</td></tr><tr><td>Toscacalm</td><td>Genepharm</td></tr><tr><td>Velasor</td><td>Vocate</td></tr><tr><td>Vienoks</td><td>Toprak</td></tr><tr><td>Voir</td><td>Velka</td></tr><tr><td>Xicotil</td><td>Aristopharma</td></tr><tr><td>Zibelant</td><td>Chrispa</td></tr><tr><td>Zikaral</td><td>Sanovel</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/cyclooxygenase-inhibitors">Cyclooxygenase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>59804-37-4</td></tr><tr><th>Weight</th><td>Average: 337.374<br>Monoisotopic: 337.019097235</td></tr><tr><th>Chemical Formula</th><td>C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>WZWYJBNHTWCXIM-RAXLEYEMSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,18H,1H3,(H,14,15)/b13-10-</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3Z)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-2H,3H,4H-1$l^{6},5,2-thieno[2,3-e][1$l^{6},2]thiazine-1,1,4-trione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN1\C(=C(/O)NC2=CC=CC=N2)C(=O)C2=C(C=CS2)S1(=O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Thienothiazines</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Thienothiazines</td></tr><tr><th>Alternative parents</th><td>Aminopyridines and Derivatives; Thiophenes; Sulfonamides; Ketones; Polyamines</td></tr><tr><th>Substituents</th><td>aminopyridine; pyridine; sulfonamide; sulfonic acid derivative; thiophene; ketone; polyamine; amine; carbonyl group; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the thienothiazines. These are heterocyclic compounds containing a thiophene ring fused to a thiazine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.</td></tr><tr><th>Pharmacodynamics</th><td>Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.</td></tr><tr><th>Mechanism of action</th><td>The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.</td></tr><tr><th>Absorption</th><td>Oral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%).</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>99%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Tenoxicam is metabolized in the liver to several pharmacologically inactive metabolites (mainly 5'-hydroxy-tenoxicam).</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tenoxicam</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00306">5'-Hydroxytenoxicam</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/307">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>72 hours (range 59 to 74 hours)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9955</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9455</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5536</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7976</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8024</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9191</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Substrate</td>
        <td>0.6922</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8896</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7105</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.7661</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8966</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9057</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8655
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7271
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.936
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.4010 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9633
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8785
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The NSAID, tenoxicam, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00630">Alendronate</a></td><td>Increased risk of gastric toxicity</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The NSAID, tenoxicam, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00310">Chlorthalidone</a></td><td>Tenoxicam may antagonize the blood pressure lowering effect of Chlorthalidone. Monitor for changes in the therapeutic effect of Chlorthalidone if Tenoxicam is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>Cholestyramine may decrease the serum concentration of Tenoxicam by increasing clearance. Monitor for changes in Tenoxicam therapeutic and adverse effects if Cholestyramine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00999">Hydrochlorothiazide</a></td><td>Tenoxicam may antagonize the blood pressure lowering effect of Hydrochlorothiazide. Monitor for changes in the therapeutic effect of Hydrochlorothiazide if Tenoxicam is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Tenoxicam may increase the serum concentration of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>Tenoxicam may increase the serum concentration of Methotrexate by reducing renal tubular secretion of Methotrexate. Monitor for changes in Methotrexate therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00524">Metolazone</a></td><td>Tenoxicam may antagonize the blood pressure lowering effect of Metolazone. Monitor for changes in the therapeutic effect of Metolazone if Tenoxicam is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>